There are other biologic agents targeting different cytokines (e.g IL-17, IL-23, IL-12 inhibitors) that are approved for use in patients with autoimmune disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. This evidence concerns the gene IL17A and autoimmune disease.